We are live on
!
Find out more
PI
Pennant Investors Portfolio holdings
AUM
$361M
1-Year Est. Return
134.26%
This Fund
S&P 500
This Quarter
Est. Return
+13.88%
1 Year Est. Return
+134.26%
3 Year Est. Return
+359.01%
5 Year Est. Return
+289.76%
10 Year Est. Return
–
AUM
$458M
AUM Growth
+$181M
(+65%)
Cap. Flow
+$134M
Cap. Flow
% of AUM
29.16%
Top 10 Holdings %
Top 10 Hldgs %
94.72%
Holding
45
New
32
Increased
1
Reduced
–
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ECHO
EchoStar
ECHO
|
+$27.7M |
| 2 |
Perimeter Solutions
PRM
|
+$2.69M |
| 3 |
Zentalis Pharmaceuticals
ZNTL
|
+$473K |
| 4 |
Arcutis Biotherapeutics
ARQT
|
+$465K |
| 5 |
KYNB
Kyntra Bio
KYNB
|
+$464K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
DISH
DISH Network Corp.
DISH
|
+$24.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Communication Services | 19.22% |
| 2 | Consumer Discretionary | 16.46% |
| 3 | Technology | 16.31% |
| 4 | Industrials | 9.34% |
| 5 | Energy | 4.52% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Arcturus Therapeutics
ARCT
$211M
| $413K | 0.09% |
+13,100
| New | +$311K |
|
27
Allogene Therapeutics
ALLO
$694M
| $412K | 0.09% |
+128,400
| New | +$364K |
|
28
Seres Therapeutics
MCRB
$48.9M
| $409K | 0.09% |
+14,615
| New | +$384K |
|
29
Zymeworks
ZYME
$1.67B
| $402K | 0.09% |
+38,700
| New | +$308K |
|
|
AGEN
30
Agenus
AGEN
$290M
| $389K | 0.08% |
+23,480
| New | +$389K |
|
|
SAGE
31
DELISTED
Sage Therapeutics
SAGE
| $379K | 0.08% |
+17,500
| New | +$347K |
|
32
Erasca
ERAS
$6.39B
| $354K | 0.08% |
+166,200
| New | +$350K |
|
33
Agios Pharmaceuticals
AGIO
$1.93B
| $336K | 0.07% |
+15,100
| New | +$338K |
|
34
Enanta Pharmaceuticals
ENTA
$400M
| $330K | 0.07% |
+35,100
| New | +$327K |
|
35
uniQure
QURE
$3.22B
| $328K | 0.07% |
+48,500
| New | +$321K |
|
|
GETR
36
DELISTED
Getaround, Inc.
GETR
| $317K | 0.07% |
1,348,153
| – | – |
|
37
Compass Therapeutics
CMPX
$387M
| $310K | 0.07% |
+199,000
| New | +$344K |
|
38
Novavax
NVAX
$1.31B
| $289K | 0.06% |
+60,300
| New | +$369K |
|
39
Replimune Group
REPL
$1.01B
| $257K | 0.06% |
+30,500
| New | +$354K |
|
40
BioXcel Therapeutics
BTAI
$27.8M
| $248K | 0.05% |
+5,244
| New | +$292K |
|
|
KLRS
41
Kalaris Therapeutics
KLRS
$96.8M
| $147K | 0.03% |
+9,378
| New | +$370K |
|
|
BLUE
42
DELISTED
bluebird bio
BLUE
| $121K | 0.03% |
+4,370
| New | +$266K |
|
|
MIMO
43
DELISTED
Airspan Networks Holdings Inc
MIMO
| $94.3K | 0.02% |
1,047,473
| – | – |
|
44
Grab Holdings Warrant
GRABW
$738K
| $18K | ﹤0.01% |
80,000
| – | – |
|
|
DISH
45
DELISTED
DISH Network Corp.
DISH
| – | – |
-4,150,000
| Closed | -$24.3M |
|
Similar funds
BCC
PPG
PWC
MCM
SWM
RA
WIP
A6
Pennant Investors's Q4 2023 Portfolio in Review
As of Q4 2023, Pennant Investors held 45 positions worth $458M, up 65% from $277M the previous quarter. Its ten largest holdings account for 95% of the portfolio.
Pennant Investors deployed $134M of net new capital in Q4 2023, opening 32 new positions and adding to 1 existing holding. Its largest new stake was EchoStar: 2,153,209 shares worth $35.7M.
By sector, the portfolio is most concentrated in Communication Services at 19% of assets, down from 27% a quarter earlier, followed by Consumer Discretionary and Technology.
On the sell side, the most notable exit was DISH Network Corp., an estimated $24.3M sold.
- Pennant Investors's largest Q4 2023 buy was EchoStar: 2,153,209 shares worth $35.7M.
- Pennant Investors added most to Perimeter Solutions in Q4 2023, an estimated $2.69M increase.
- Pennant Investors fully exited DISH Network Corp. in Q4 2023, selling an estimated $24.3M.
- Pennant Investors's ten largest holdings make up 95% of its $458M portfolio in Q4 2023.
- Pennant Investors opened 32 new positions and closed 1 in Q4 2023.
- Pennant Investors's portfolio value rose 65% quarter-over-quarter to $458M.
Based on Pennant Investors's 13F filing for Q4 2023, filed 14 Feb 2024.